Intestinal microbiome in patients with chronic pancreatitis

Czech version

Authors: David Solil ¹; Petr Dítě ^1,2; Marie Přecechtělová ¹; Magdalena Uvírová ³; Jiří Dolina ^1,4; Arnošt Martínek ^2,5
Authors‘ workplace: Interní gastroenterologická klinika LF MU a FN Brno ¹; Lékařská fakulta OU, Ostrava ²; EUC Laboratoře CGB a. s., Ostrava ³; Lékařská fakulta MU, Brno 5 Interní kardiologická klinika, FN Ostrava ⁴
Published in: Gastroent Hepatol 2024; 78(3): 242-246
Category:
doi: https://doi.org/10.48095/ccgh2024242

Overview

We refer to the microflora inhabiting the intestine as a whole as the intestinal microbiota, and their genomes collectively as the microbiome. Dysbiosis is a violation of the balance between the intestinal microbiota, the immune system and the epithelial intestinal barrier. Dysbiosis is associated not only with a number of gastrointestinal diseases, including inflammatory and cancerous diseases of the pancreas. We do not know the answer as to whether dysbiosis is a causal factor in the development of chronic pancreatitis, but it is a fact that, for example, the severity of the disease or changes in exocrine or endocrine pancreatic function are related to the intestinal microbiota. Pancreatic enzymes, especially pancreatic elastase, are significantly involved in the modulation of intestinal microflora. Specific changes in the composition of the intestinal microbiome in people with an autoimmune form of chronic pancreatitis could also become early diagnostic markers of the disease. It is evident that systematic research is more than desirable in this area of pancreatology.

Keywords:

intestinal microbiome – chronic pancreatitis – autoimmune pancreatitis – diabetes mellitus – exocrine pancreatic insufficiency – corticoids

Sources

1. Ramakrishma BS. Role of the gut microbiota in human nutrition and metabolism. Gastroenterol Hepatol 2013; 28 (4): 9–17. doi: 10.1111/jgh. 12294.

2. Schepis T, De Lucia SS, Nista EC et al. Microbiota in Pancreatic Diseases: A Review of the Literature. J Clin Med 2021; 10 (24): 5920. doi: 10.3390/jcm10245920.

3. Pagliari D, Saviano A, Newton EE et al. Gut Microbiota-Immune System Crosstalk and Pancreatic Disorders. Mediators Inflamm 2018; 2018: 7946431. doi: 10.1155/2018/7946431.

4. Ammer-Herrmenau C, Pfisterer N, Weingarten MF et al. The microbiome in pancreatic diseases: Recent advances and future perspectives. United European Gastroenterol J 2020; 8 (8): 878–885. doi: 10.1177/2050640620944720.

5. Uronis JM, Mühlbauer M, Herfarth HH et al. Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility. PLoS One 2009; 4 (6): e6026. doi: 10.1371/journal.pone.0006026.

6. Beyer G, Habtezion A, Werner J et al. Chronic pancreatitis. Lancet 2020; 396 (10249): 499–512. doi: 10.1016/S0140-6736 (20) 31318-0.

7. Zhou CH, Meng YT, Xu JJ et al. Altered diversity and composition of gut microbiota in Chinese patients with chronic pancreatitis. Pancreatology 2020; 20 (1): 16–24. doi: 10.1016/j.pan.2019.11.013.

8. Ritz S, Hahn D, Wami HT et al. Gut microbiome as a response marker for Pancreatic enzyme replacement therapy in a porcine model of exocrine pancreas insufficiency Microb Cell Fact 2020; 19 (1): 221. doi: 10.1186/s129 34-020-01482-2.

9. Jandhyala SM, Madhulika A, Deepika G et al. Altered intestinal microbiota in patients with chronic pancreatitis: implication in diabetes and metabolic abnormalities. Sci Rep 2017; 7: 43640. doi: 10.1038/srep43640.

10. Frost F, Kacprowski T, Rühlemann M et al. Impaired Exocrine Pancreatic Function Associates With Changes in Intestinal Microbiota Composition and Diversity. Gastroenterology 2019; 156 (4): 1010–1015. doi: 10.1053/j.gastro.2018.10.047.

11. Nishiyama H, Nagai T, Kudo M et al. Supplementation of pancreatic digestive enzymes alters the composition of intestinal microbiota in mice. Biochem Biophys Res Commun 2018; 495 (1): 273–279. doi: 10.1016/j.bbrc.2017.10.130.

12. Chelakkot C, Choi Y, Kim DK et al. Akkermansia muciniphila-derived extracellular vesicles influence gut permeability through the regulation of tight junctions. Exp Mol Med 2018; 50 (2): e450. doi: 10.1038/emm.2017.282.

13. Wu H, Xie S, Miao J et al. Lactobacillus reuteri maintains intestinal epithelial regeneration and repairs damaged intestinal mucosa. Gut Microbes 2020; 11 (4): 997–1014. doi: 10.1080/1949 0976.2020.1734423.

14. Wang W, Xiao Y, Wang X et al. Disordered gut microbiota in children who have chronic pancreatitis and different functional gene mutations. Clin Transl Gastroenterol 2020; 11 (3): e00150. doi: 10.14309/ctg.0000000000000150.

15. Yadav SK, Boppana S, Ito N et al. Gut dysbiosis breaks immunological tolerance toward the central nervous system during young adulthood. Proc Natl Acad Sci USA 2017; 114 (44): E9318–E9327. doi: 10.1073/pnas.1615715114.

16. Alipour M, Zaidi D, Valcheva R et al. Mucosal Barrier Depletion and Loss of Bacterial Diversity are Primary Abnormalities in Paediatric Ulcerative Colitis. J Crohns Colitis 2016; 10 (4): 462–471. doi: 10.1093/ecco-jcc/jjv223.

17. Duboc H, Rajca S, Rainteau D et al. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut 2013; 62 (4): 531–539. doi: 10.1136/gutjnl-2012-302578.

18. Shimosegawa T, Chari ST, Frulloni L et al. International Association of Pancreatology. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas 2011; 40 (3): 352–358. doi: 10.1097/MPA.0b013e3182142fd2.

19. Fukui Y, Uchida K, Sakaguchi Y et al. Possible involvement of Toll-like receptor 7 in the development of type 1 autoimmune pancreatitis. J Gastroenterol 2015; 50 (4): 435–444. doi: 10.1007/s00535-014-0977-4.

20. Minaga K, Watanabe T, Arai Y et al. Activation of interferon regulatory factor 7 in plasmacytoid dendritic cells promotes experimental autoimmune pancreatitis. J Gastroenterol 2020; 55 (5): 565–576. doi: 10.1007/s00535-020-01662-2.

21. Jiao Y, Wu L, Huntington ND et al. Crosstalk Between Gut Microbiota and Innate Immunity and Its Implication in Autoimmune Dis- eases. Front Immunol 2020; 11: 282. doi: 10.3389/fimmu.2020.00282.

22. Kamata K, Watanabe T, Minaga K et al. Gut microbiome alterations in type 1 autoimmune pancreatitis after induction of remission by prednisolone. Clin Exp Immunol 2020; 202 (3): 308–320. doi: 10.1111/cei.13509.

ORCID autorů

P. Dítě 0000-0002-0086-5421,

M. Uvírová 0000-0002-2783-5724,

J. Dolina 0000-0002-9061-5273,

A. Martínek 0000-0001-7597-3235.

Doručeno/Submitted: 19. 2. 2024

Přijato/Accepted: 19. 4. 2024

prof. MUDr. Petr Dítě, DrSc.

Interní gastroenterologická klinika

LF MU a FN Brno

Jihlavská 340/20

625 00 Brno